secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZEVRA THERAPEUTICS, INC. (ZVRA)
CIK:        0001434647
Form:       8-K
Filed at:   2023-03-07T23:59:59+00:00
Accession:  0001437749-23-005593
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zevra reports Q4 net loss $9.0M ($0.26/sh); cash $102.9M; arimoclomol NDA resubmission on track for Q3 2023
--------------------------------------------------------------------------------

- Q4 net revenue $2.3M (vs $2.6M in Q4 2021); net loss ($9.0M) or ($0.26)/share vs ($2.7M)/($0.08).
- FY 2022 net revenue $10.5M (down from $28.7M); net loss ($41.5M) or ($1.20)/share vs ($62.9M)/($2.11) in 2021.
- Cash, cash equivalents and investments $102.9M as of Dec 31, 2022; cash runway extended into 2026.
- Arimoclomol NDA resubmission for NPC anticipated as early as Q3 2023.
- KP1077 Phase 2 trial for IH: interim data expected as early as Q3 2023, top-line by year-end 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434647/000143774923005593/0001437749-23-005593-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434647/000143774923005593/kmph20221130_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-005593

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer